NCT04798989View on ClinicalTrials.gov

A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology

PHASE2TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 2, 2021

Primary Completion Date

November 28, 2022

Study Completion Date

November 28, 2022

Conditions
Alzheimer's Disease With Vascular Pathology
Interventions
DRUG

CY6463

CY6463 Oral Tablet

DRUG

Placebo

Placebo Oral Tablet

Trial Locations (5)

33125

Optimus U Corp, Miami

40536

University of Kentucky, Lexington

85258

Clinical Endpoints, Scottsdale

96817

Hawaii Pacific Neurosciences, LLC, Honolulu

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
lead

Tisento Therapeutics

INDUSTRY

NCT04798989 - A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology | Biotech Hunter | Biotech Hunter